Zimmer Biomet Holdings ((ZBH)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Zimmer Biomet Holdings is conducting a Post Market Clinical Follow-up (PMCF) study titled ‘Post Market Clinical Follow up Study to Provide Safety, Performance and Clinical Benefits Data of the Taperloc Complete Stems.’ The study aims to gather data on the safety, performance, and clinical benefits of the Taperloc Complete Stems used in total hip arthroplasty procedures, with follow-ups at 1, 3, 5, 7, and 10 years. This study is significant as it seeks to validate the long-term effectiveness of these implants.
The intervention being tested is the Taperloc Complete Stem, a device implanted to address hip malfunctions or diseases. Its purpose is to improve hip function and alleviate associated conditions such as arthritis and chronic pain.
The study is observational, following a cohort model with a prospective time perspective. This means it observes a group of patients over time to assess outcomes without altering their treatment. The primary goal is to collect real-world data on the device’s performance.
The study began on July 18, 2019, and is currently recruiting participants. The primary completion date is yet to be announced, but the last update was submitted on March 10, 2025. These dates are crucial as they indicate the study’s progress and timeline for data collection.
This clinical study update could influence Zimmer Biomet’s stock performance and investor sentiment positively, as successful outcomes may enhance the company’s market position in the orthopedic device industry. Competitors in the sector will likely monitor these developments closely.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.